# UK Medical Cannabis Prescriptions Hit 1.7 Million in 2025 as ACMD Review Approaches > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches/ > **Published:** 2026-08-18T17:24:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:19-04:00 > **Clinical Summary:** UK medical cannabis prescriptions hit 1.7M in 2025. ACMD review approaches with focus on real-world outcomes and safety data. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustryPainAnxiety[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) Why This Matters As [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) prescriptions in the UK reach 1.7 million annually, clinicians need current evidence on efficacy and safety profiles across common indications to make informed prescribing decisions for their patients. The approaching ACMD review will likely reshape regulatory frameworks and access pathways, directly affecting which patients can legally obtain [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) and under what clinical circumstances. Tracking prescription volumes and outcomes data helps clinicians understand real-world effectiveness patterns and identify which patient populations may benefit most from cannabis-based interventions versus conventional therapies. Clinical Summary [Medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) prescriptions in the United Kingdom reached 1.7 million in 2025, representing substantial growth in clinical utilization and suggesting increasing physician acceptance of cannabis-based medicines within the National Health Service framework. This expansion occurs as the Advisory Council on the Misuse of Drugs (ACMD) prepares to conduct a comprehensive review of medical cannabis policy, which will likely shape future prescribing guidelines and regulatory requirements. The reported alignment between supply and demand indicates a maturing market with improved access and distribution infrastructure for patients seeking [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). The upcoming ACMD review will be critical in determining whether additional indications, formulations, or patient populations should be included in the medical cannabis framework, potentially affecting prescriber confidence and utilization patterns. For clinicians in the UK and other jurisdictions considering medical cannabis adoption, the scale of these prescriptions and the formal policy review signal growing clinical legitimacy, though evidence-based outcome measurement will be essential to justify continued expansion and secure long-term integration into standard care pathways. Dr. Caplan’s Take “We’re seeing real-world utilization data now from the UK that gives us important context, but prescription volume alone doesn’t tell us about efficacy or safety outcomes, which is exactly what the ACMD review should be examining. Until we have systematic data on which patients benefit, which don’t, and what the actual harms are in practice, we’re still operating with incomplete clinical intelligence.” Clinical Perspective 💊 The substantial growth in UK medical cannabis prescriptions to 1.7 million in 2025 reflects increasing clinician familiarity and patient demand, yet this expansion occurs amid ongoing uncertainty about long-term efficacy, optimal dosing strategies, and [comparative effectiveness](https://cedclinic.com/psychedelic-therapies-for-depression-efficacy-debate/) against conventional therapies for most conditions. The apparent alignment between supply and demand suggests a maturing market, though prescribing patterns may reflect enthusiasm that outpaces robust outcome data rather than clearly established clinical superiority in most indications beyond well-studied conditions like treatment-resistant epilepsy. Clinicians should recognize that increased prescription volume does not inherently validate therapeutic benefit, and the forthcoming ACMD review will be critical in establishing evidence-based criteria for appropriate use. As medical cannabis becomes more embedded in routine practice, healthcare providers need to systematically collect and report outcomes data on their patient populations to contribute to the evidence base and ensure prescribing decisions are grounded in demonstrated benefit rather 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20UK%20Medical%20Cannabis%20Prescriptions%20Hit%201.7%20Million%20in%202025%20as%20ACMD%20Review%20Approaches%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74322)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74322)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20UK%20Medical%20Cannabis%20Prescriptions%20Hit%201.7%20Million%20in%202025%20as%20ACMD%20Review%20Approaches%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74322)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://businessofcannabis.com/uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches/](https://businessofcannabis.com/uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).